STAT April 17, 2024
Elaine Chen

Eli Lilly reported positive results for its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.

The results also pave the way for Zepbound to potentially become the first approved treatment for obstructive sleep apnea, or OSA, a common disorder characterized by breathing interruptions during sleep.

In one year-long Phase 3 study that looked...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
Pharma Pulse 4/29/24: Examining Drug Shortages Before and During the COVID-19 Pandemic, Saudi Arabia Spends Big to Become an AI Superpower & more
Lean Digital: How Apps and Services Can Help Control Weight
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
An Oveview of the Nation’s Largest SEED Fund

Share This Article